Advisers to the U.S. government are gathering Wednesday to evaluate a novel blood test that aims to identify signs of multiple cancers in healthy individuals, marking the technology's initial major regulatory hurdle.
Developed by Grail Inc., the screening checks for fragments of DNA released by tumor cells, an emerging approach that seeks to identify various forms of malignancy through a single routine blood draw.
